From the Microsoft AI:

"CCR5 is expressed in pancreatic cancer cells and plays a significant role in their invasive potential. Here are some key points:

CCR5 Expression in Pancreatic Cancer Cells:
In vitro experiments with human pancreatic cancer cell lines (AsPc-1, BxPc-3, and MIA PaCa-2) have shown higher expression levels of CCR51.
The activation of pancreatic cancer cells expressing CCR5 by CCL5 increases their invasive potential1.
CCR5 and Tumor Microenvironment:
In pancreatic adenocarcinoma, tumor cells produce increased levels of ligands for the CCR5 chemokine receptor2.
This leads to a higher expression of CCR5 on immune cells within the tumor microenvironment2.
CCR5 as a Therapeutic Target:
The treatment with CCR5 inhibitor maraviroc inhibited the CCL5 activation, suggesting that blocking the CCR5/CCL5 axis might prove beneficial to prevent metastasis and provide a more therapeutic strategy to control pancreatic cancer progression1.
In summary, CCR5 is expressed in pancreatic cancer cells and contributes to their invasive potential. It is also a promising therapeutic target for pancreatic cancer treatment.